Autres langues Poseida Therapeutics, Inc.

Actions

PSTX

US73730P1084

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
2,77 ^USD	+14,46%		+33,82%	-17,56%

08/04	Poseida Therapeutics, Inc. Présente de nouvelles données de phase 1 à l'AACR 2024 soutenant le potentiel de la thérapie CAR-T allogénique P-BCMA-Allo1 pour bénéficier à un large éventail de patients atteints de myélome multiple.	CI
25/03	Poseida Therapeutics, Inc. nomme Syed Rizvi au poste de Chief Medical Officer à compter du 1er avril 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	03:31
Malin Corp investee signs agreement with Astellas Pharma	01/05
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	01/05
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01/05
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01/05
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	19/04
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	17/04
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	08/04
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/04
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25/03
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	25/03
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	07/03
Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K	07/03
Poseida Therapeutics, Inc. Announces Executive Changes	07/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04/03
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	15/12
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	11/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Poseida Therapeutics, Inc.

Actions

PSTX

US73730P1084

Autres langues

Filtres